Study of SYS6005 for advanced solid tumors and lymphomas
Part of Cancer clinical trials.
This study tests a new drug (SYS6005) that targets a protein called ROR1 on certain cancer cells. It is for people with advanced solid tumors or B-cell lymphomas that have stopped responding to other treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older.
- You must have a type of advanced cancer (solid tumor or lymphoma) that has not responded to standard treatments or you cannot tolerate them.
- You must have at least one tumor or lymph node that can be seen on scans (like CT or MRI).
- You must be in reasonably good health, with your liver, kidneys, and bone marrow working well (based on blood tests).
- You must not have untreated or active brain tumors that cause symptoms or need treatment.
- You cannot have had prior treatment with a ROR1-targeted drug or a specific type of antibody-drug conjugate (ADC) that contains MMAE.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug, SYS6043, for people with advanced solid tumors that have not responded to standard treatments. The goal is to see if the drug can help shrink or control the tumor.
This trial tests a new drug, ISM8207, for people with advanced solid tumors or certain B-cell lymphomas that have not responded to standard treatments. It aims to see if the drug is safe and effective.
This trial tests a new drug called SYS6040 for people with advanced solid tumors that have stopped responding to standard treatments. It aims to see if the drug is safe and effective.
This trial tests a new drug called SYS6055 for people with B-cell cancers (leukemia or lymphoma) that have not improved or have come back after standard treatments. It aims to see if the drug is safe and effective.
This Phase 1 study tests whether a new drug called SYS6051 is safe and effective for people with advanced solid tumors (cancer that has spread). Researchers will evaluate how well your body tolerates the drug and monitor for side effects.
This trial tests a new study drug (SYS6043) for people with advanced or metastatic solid tumors that have not responded to or are not candidates for standard therapies. The drug targets a protein called B7-H3 on cancer cells to help stop tumor growth.
Hear when a new B Cell Malignancies trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.